Drugs Made In America Acquisition (DMAA) EPS (Basic) (2025)

Drugs Made In America Acquisition's (DMAA) quarterly EPS (Basic) came in at -$0.09 in Q4 2025, down 234.35% on a QoQ basis from $0.07 in Q3 2025.

Drugs Made In America Acquisition (DMAA) EPS (Basic) (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of EPS (Basic) data on file, last reported at -$0.09 in Q4 2025.

Quarterly EPS (Basic) changed N/A year-over-year to -$0.09 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $0.1 (changed N/A YoY) and the FY2025 annual result came in at $0.09, up 387.72% from the prior year.
EPS (Basic) declined to -$0.09 in Q4 2025, from $0.07 in the prior quarter.
In the past five years, EPS (Basic) ranged from a high of $0.07 in Q2 2025 to a low of -$0.09 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Oxley Bridge Acquisition	585.76 Mn	585.76 Mn	-	0.07
2	Launch Two Acquisition	557.86 Mn	557.86 Mn	-	0.07
3	Drugs Made In America Acquisition	506.00 Mn	506.00 Mn	-	0.07
4	Cantor Equity Partners IV	468.00 Mn	468.00 Mn	-	0.07
5	New Providence Acquisition Corp. III	401.18 Mn	401.18 Mn	-	0.07
6	GP-Act III Acquisition	401.06 Mn	401.06 Mn	-	0.01
7	Aldel Financial	397.49 Mn	397.49 Mn	-	0.09
8	Pioneer Acquisition I	390.89 Mn	653.32 Mn	-	-0.01
9	Republic Digital Acquisition	389.25 Mn	388.51 Mn	-	0.07
10	Drugs Made In America Acquisition	215.62 Mn	215.62 Mn	-	0.06

Download Data